Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.

Expert Review of Hematology
Tsering Gyalpo LamaSusan O'Brien

Abstract

Development of the BTK inhibitor ibrutinib has changed the landscape of CLL treatment producing durable responses with minimal to no myelosuppression. Although remissions are durable, relapses remain a challenge. Data from recent studies indicate that most patients relapsing on ibrutinib have mutations in BTK or PLCG2. The result of the C418S mutation in BTK is loss of covalent binding of ibrutinib to BTK resulting in reversible, transient inhibition in BTK mutant patients. There is downstream gain of function of BCR signaling with PLCG2 mutations allowing continued cell proliferation despite inhibition of BTK by ibrutinib. Agents targeting other pathways such as the BCL2 pathway, or agents binding to other BTK binding sites are promising therapies in patients with BTK-mutated resistance. Authors conducted a review of available literature on mechanism of ibrutinib resistance and management using PubMed, Medline, EMBASE, Cochrane Central, Google Scholar, and ClinicalTrials.gov. The current approach is to offer a clinical trial or the BCL2 inhibitor venetoclax to patients with ibrutinib-resistant CLL. We await more data from ongoing clinical trials combining different targeted therapies or using reversible BTK inhibitors will pro...Continue Reading

References

Dec 1, 1969·The Australian Journal of Experimental Biology and Medical Science·D NaorG Cividalli
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia-Maria TsimberidouMichael J Keating
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Dec 13, 2006·ChemMedChem·Zhengying PanJames T Palmer
Oct 16, 2009·Annual Review of Immunology·Tomohiro KurosakiYoshihiro Baba
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Jun 21, 2012·Blood·Jennifer A WoyachJohn C Byrd
Aug 7, 2012·Current Oncology Reports·Ines M Macias-Perez, Ian W Flinn
Jan 15, 2013·Community Oncology·Loretta J Nastoupil, Christopher R Flowers
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Aug 7, 2013·Hematology/oncology Clinics of North America·Nitin Jain, Susan O'Brien
Aug 21, 2013·Journal of Hematology & Oncology·Akintunde AkinleyeDelong Liu
Sep 26, 2013·Nature Reviews. Cancer·Caitriona HolohanPatrick G Johnston
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
May 30, 2014·The New England Journal of Medicine·Richard R FurmanY Lynn Wang
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Natalia L KomarovaDominik Wodarz
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Mar 3, 2015·Proceedings of the National Academy of Sciences of the United States of America·Idit Sagiv-BarfiRonald Levy
Mar 7, 2015·Blood·Mazie TsangSameer A Parikh
Mar 27, 2015·American Journal of Hematology·Anthony MatoStephen J Schuster
Apr 11, 2015·British Journal of Haematology·Shuang Q ZhangYue Lynn Wang
Aug 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Sep 4, 2016·Journal of Hematology & Oncology·Jingjing WuDelong Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.